Allakos Inc.

Equities

ALLK

US01671P1003

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:02 2024-04-18 pm EDT			5-day change	1st Jan Change
1.07 ^USD	+0.94%		-11.57%	-60.81%

Mar. 15	North American Morning Briefing : Inflation Worries Continue to Weigh on Mood	DJ
Mar. 14	Allakos Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Allakos Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022

August 04, 2022 at 04:49 pm EDT

Allakos Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported net loss was USD 49.1 million compared to USD 57.21 million a year ago. Basic loss per share from continuing operations was USD 0.9 compared to USD 1.07 a year ago.
For the six months, net loss was USD 246.13 million compared to USD 112.77 million a year ago. Basic loss per share from continuing operations was USD 4.5 compared to USD 2.11 a year ago.

Latest news about Allakos Inc.

North American Morning Briefing : Inflation Worries Continue to Weigh on Mood	Mar. 15	DJ
Allakos Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
Allakos Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 14	CI
Allakos Inc. Announces Publication Highlighting AK006 Mast Cell Inhibition	Feb. 12	CI
North American Morning Briefing : TSMC Results -2-	Jan. 18	DJ
Sector Update: Health Care Stocks Slipping Late Afternoon	Jan. 17	MT
Sector Update: Health Care	Jan. 17	MT
Top Midday Decliners	Jan. 17	MT
Allakos Shares Fall After Downgrades by Jefferies, Cantor Fitzgerald, Lifesci Capital	Jan. 17	MT
JMP Securities Adjusts Allakos' Price Target to $3 From $10, Maintains Market Outperform Rating	Jan. 17	MT
Barclays Trims Allakos' Price Target to $1 From $1.50, Maintains Underweight Rating	Jan. 17	MT
Jefferies Downgrades Allakos to Hold From Buy, Adjusts Price Target to $1.50 From $6	Jan. 17	MT
Sector Update: Health Care Stocks Weaker Late Afternoon	Jan. 16	MT
Cantor Fitzgerald Downgrades Allakos to Neutral From Overweight	Jan. 16	MT
Lifesci Capital Downgrades Allakos to Market Perform From Outperform	Jan. 16	MT
Sector Update: Health Care Stocks Softer Tuesday Afternoon	Jan. 16	MT
Sector Update: Health Care	Jan. 16	MT
Allakos to Cut Workforce in Restructuring After Lirentelimab Trials Fail to Meet Targets; Shares Drop	Jan. 16	MT
Traders Digest More Bank Earnings, Fueling Narrow Premarket Losses for US Equity Futures	Jan. 16	MT
Transcript : Allakos Inc. - Special Call	Jan. 16
Allakos to stop further development of skin disease drug, plans job cuts	Jan. 16	RE
Allakos says experimental skin disease drug fails mid-stage studies	Jan. 16	RE
Allakos Announces Restructuring to Focus on Development of AK006	Jan. 16	CI
Allakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Did Not Meet Their Primary Endpoints	Jan. 16	CI
North American Morning Briefing : S&P 500 Eyes -2-	Dec. 19	DJ

Chart Allakos Inc.

Duration

Period

More charts

Company Profile

Allakos Inc. is a clinical-stage biotechnology company, which is engaged in the development of therapeutics that target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases. The Companyâs most advanced product candidate, AK006, is in a Phase I clinical trial. AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. It is developing AK006 for the treatment of CSU and potentially other indications. AK006 has completed preclinical testing, and in these studies, it has demonstrated that binding of AK006 to Siglec-6 inhibits multiple modes of mast cell activation, including IgE, IL-33, KIT, C5a and MRGPR-X2. In addition to mast cell inhibition, AK006 reduced human tissue mast cells via ADCP in the presence of activated macrophages. The Company is also developing lirentelimab (AK002) and, in conjunction with the Phase II, lirentelimab results in atopic dermatitis and chronic spontaneous urticaria.

Sector

Biotechnology & Medical Research

Calendar

2024-05-06 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

1.06 USD

Average target price

2.9 USD

Spread / Average Target

+173.58%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ALLAKOS INC.	-60.81%	93.15M
VERTEX PHARMACEUTICALS INCORPORATED	-3.30%	102B
REGENERON PHARMACEUTICALS, INC.	+1.79%	96.84B
ARGENX SE	-0.44%	21.48B
BIONTECH SE	-18.35%	20.82B
GENMAB A/S	-7.45%	18.6B
WUXI APPTEC CO., LTD.	-40.31%	16.81B
BEIGENE, LTD.	-26.84%	13.78B
NEUROCRINE BIOSCIENCES, INC.	+0.59%	13.4B
SAREPTA THERAPEUTICS, INC.	+20.86%	11.06B

Bio Therapeutic Drugs